Investor Webinar and Analyst Briefing

Cambridge Cognition Holdings PLC

26 April 2023

 

REACH

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Investor Webinar and Analyst Briefing

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, will be announcing the Company's preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased to provide details of an investor webinar and analyst briefing being held on that day.

Investor Webinar

Cambridge Cognition's management will be hosting an online presentation and Q&A session at 5.30 p.m. BST on Wednesday 3 May 2023. This session is open to all existing and prospective shareholders. Those wishing to attend should email [e-mail] and they will be provided with log in details.

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [e-mail] .

Analyst Briefing

The Company's management will be hosting a presentation for analysts on the day of results at 9:30 a.m. BST, those who wish to attend the briefing should register their interest with Zach Cohen at [e-mail] or on 020 3934 6637.

Enquiries

Cambridge Cognition Holdings Plc Matthew Stork, Chief Executive Officer Stephen Symonds, Chief Financial Officer	Tel: [phone] [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Joint Broker) Freddy Crossley / Emma Earl  Rupert Dearden	Tel: [phone] (Corporate Finance) (Corporate Broking)
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant	Tel: [phone]
IFC Advisory Ltd (Financial PR and IR) Tim Metcalfe / Graham Herring / Zach Cohen	Tel: [phone]  [e-mail]

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

END